| Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. | |
| | |
MedLine Citation:
|
PMID: 23387937 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
ABSTRACT Progression or relapse occurs in the vast majority of patients with multiple myeloma (MM) who undergo up-front autologous haematopoietic cell transplantation (AHCT1), which remains a cornerstone of treatment in the era of novel agents. Limited data are available regarding the value of salvage therapy with a second AHCT (AHCT2) in patients who relapse/progress after AHCT1. We analysed the outcome of 83 patients who underwent salvage AHCT2 between 1994 and 2011. Most patients (77%) had received treatment with novel agents between AHCT1 and AHCT2, and 28% of patients were from ethnic minority groups. Median overall survival (OS) from AHCT2 was 31.5 months (95%CI: 22 - 41), and median progression-free survival (PFS) was 15.5 months (95%CI: 11-20). In multivariate analysis, only disease status (≥PR) at AHCT2 was associated with better OS. The 3-year OS rates for patients receiving AHCT2 in >PR and PR were 85.9% (95%CI: 61-96) and 51.3% (95%CI: 34-68), respectively. Disease status at AHCT2 and time to progression/relapse after AHCT1 were associated with PFS in multivariate analysis. In summary, salvage AHCT2 is an effective treatment option in patients with chemosensitive relapse/progression and prolonged remission after a prior autograft. |
| | |
Authors:
|
Holger W Auner; Richard Szydlo; Alero Rone; Aristeidis Chaidos; Chrissy Giles; Ed Kanfer; Donald H Macdonald; David Marin; Dragana Milojkovic; Jiri Pavlu; Jane F Apperley; Amin Rahemtulla |
Related Documents
:
|
11390007 - Lung cancer in patients under age 40. 8650667 - Partial wave in human seminiferous tubules appears to be a random occurrence. 23137997 - Assessment of a new scoring system for predicting non-sentinel node positivity in senti... 18486987 - Identification of a low risk subgroup of stage ib lung adenocarcinoma patients. 2333867 - Five-year survival for end-stage renal disease patients in the united states, europe, a... 2039357 - Prognosis after initial recurrence of cutaneous melanoma. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-2-7 |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: - ISSN: 1029-2403 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-2-7 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PAA-PAMPS Copolymers as an Efficient Tool to Control CaCO3 Scale Formation.
Next Document: Impedance-based outflow boundary conditions for human carotid haemodynamics.